GlassScriptPhysician profile
Asadullah Khan
NPI 1073557468
$4,150.26
in general payments reported to CMS, 2019-2025
21 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.85 · 2021: $114 · 2022: $372 · 2023: $735 · 2024: $1,536 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,646 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.43 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $755.99 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $455.86 | 2022-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $429.71 | 2021-2025 | Lupkynis |
| Amgen INC. | $345.97 | 2024-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $278.45 | 2022-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $276.78 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $270.49 | 2022-2025 | Farxiga, Lokelma |
| Daiichi Sankyo INC. | $265.09 | 2023-2025 | Injectafer |
| Vifor Pharma, INC. | $231.83 | 2019-2025 | Veltassa |
| Ardelyx, INC. | $180.15 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $137.13 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.03 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $69.98 | 2024-2025 | Vafseo |
| Novo Nordisk INC | $64.42 | 2024-2025 | |
| Travere Therapeutics, INC. | $59.32 | 2023-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $53.00 | 2024 | Terlivaz |
| Horizon Therapeutics Plc | $44.88 | 2023 | Krystexxa |
| Scpharmaceuticals INC. | $28.11 | 2025 | |
| Cormedix INC. | $26.16 | 2025 | Defencath |
| Alexion Pharmaceuticals, INC. | $25.71 | 2022 | |
| Fresenius USA Marketing, INC. | $23.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asadullah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.